8-K
filed February 13, 2025, 6:59 PM ET
ticker NMRA
CIK 0001885522
leadership
confidence high
sentiment neutral
materiality 0.75
Founder Berns becomes CEO as Gosebruch departs; option repricing approved
Neumora Therapeutics, Inc.
- Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.
- CEO Henry Gosebruch and Chief Commercial Officer Kaya Pai Panandiker leave the company.
- Joshua Pinto promoted to president (base $645k, 60% target bonus, $970k signing bonus, 3M option).
- Bill Aurora becomes COO & CDO; Michael Milligan becomes CFO; other leadership changes announced.
- Board approved option repricing subject to stockholder approval; exercise price set at Feb 13 closing price.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joshua Pinto changed role as President at Neumora Therapeutics, Inc..
- Action
- transitioned
- Role
- President
Exact text from the filing
Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Henry Gosebruch departed as President, Chief Executive Officer at Neumora Therapeutics, Inc..
- Action
- departed
- Role
- President, Chief Executive Officer
Exact text from the filing
Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Carol Suh changed role as Chief Strategy Officer at Neumora Therapeutics, Inc..
- Action
- transitioned
- Role
- Chief Strategy Officer
Exact text from the filing
Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bill Aurora changed role as Chief Operating and Development Officer at Neumora Therapeutics, Inc..
- Action
- transitioned
- Role
- Chief Operating and Development Officer
Exact text from the filing
Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.8
Jason Duncan was appointed as Chief Legal and Administrative Officer at Neumora Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Legal and Administrative Officer
Exact text from the filing
Jason Duncan will serve as Chief Legal and Administrative Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kaya Pai Panandiker departed as Chief Commercial Officer at Neumora Therapeutics, Inc..
- Action
- departed
- Role
- Chief Commercial Officer
Exact text from the filing
Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Milligan was appointed as Chief Financial Officer at Neumora Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul L. Berns changed role as Chief Executive Officer and Chairman of the Board at Neumora Therapeutics, Inc..
- Action
- transitioned
- Role
- Chief Executive Officer and Chairman of the Board
Exact text from the filing
Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.